TW202115078A - 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑 - Google Patents

咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑 Download PDF

Info

Publication number
TW202115078A
TW202115078A TW109126044A TW109126044A TW202115078A TW 202115078 A TW202115078 A TW 202115078A TW 109126044 A TW109126044 A TW 109126044A TW 109126044 A TW109126044 A TW 109126044A TW 202115078 A TW202115078 A TW 202115078A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
aryl
cycloalkyl
heteroaryl
Prior art date
Application number
TW109126044A
Other languages
English (en)
Chinese (zh)
Inventor
張國良
苗建壯
王策
Original Assignee
英屬開曼群島商百濟神州有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英屬開曼群島商百濟神州有限公司 filed Critical 英屬開曼群島商百濟神州有限公司
Publication of TW202115078A publication Critical patent/TW202115078A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW109126044A 2019-08-02 2020-07-31 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑 TW202115078A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2019099147 2019-08-02
WOPCT/CN2019/099147 2019-08-02
CN201910939816.3 2019-09-30
CN201910939816 2019-09-30
CN201911204523.7 2019-11-29
CN201911204523 2019-11-29
CN202010075950 2020-01-22
CN202010075950.6 2020-01-22

Publications (1)

Publication Number Publication Date
TW202115078A true TW202115078A (zh) 2021-04-16

Family

ID=74303609

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109126044A TW202115078A (zh) 2019-08-02 2020-07-31 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑

Country Status (7)

Country Link
US (1) US20220289752A1 (ja)
EP (1) EP4008720A4 (ja)
JP (1) JP2022542269A (ja)
KR (1) KR20220041838A (ja)
CN (2) CN114206872A (ja)
TW (1) TW202115078A (ja)
WO (1) WO2021023105A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4385985A1 (en) 2021-08-11 2024-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Heterocyclic derivative, and composition and pharmaceutical use thereof
WO2023125681A1 (en) * 2021-12-29 2023-07-06 Beigene, Ltd. Heterocyclic compounds
CN118201933A (zh) * 2021-12-30 2024-06-14 四川科伦博泰生物医药股份有限公司 一类三并环化合物、其制备方法及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396328A2 (en) * 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US11084818B2 (en) * 2016-11-11 2021-08-10 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
US11111249B2 (en) * 2017-05-18 2021-09-07 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof
CA3129178A1 (en) * 2019-02-07 2020-08-13 Beigene, Ltd. Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist

Also Published As

Publication number Publication date
JP2022542269A (ja) 2022-09-30
WO2021023105A1 (zh) 2021-02-11
CN112321590A (zh) 2021-02-05
EP4008720A4 (en) 2023-08-02
CN114206872A (zh) 2022-03-18
KR20220041838A (ko) 2022-04-01
US20220289752A1 (en) 2022-09-15
EP4008720A1 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
CA2845159C (en) Compounds and compositions as c-kit kinase inhibitors
WO2020103896A1 (en) Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
KR20220029690A (ko) HPK1 저해제로서의 피롤로[2,3-b]피라진 및 이의 용도
US20220267354A1 (en) Tricyclic compounds as hpk1 inhibitor and the use thereof
TW202115078A (zh) 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑
ES2952332T3 (es) Compuestos espirocíclicos y sus métodos de preparación y uso
CN114929689A (zh) Bcl-2抑制剂
TW202045508A (zh) 作為tlr7致效劑的咪唑并[2,1-f][1,2,4]三𠯤-4-胺衍生物
JP2023552864A (ja) Ｉｌ－１７モジュレータとしてのイミダゾピリダジン誘導体
EP4146655A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2021180103A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2021058017A1 (en) Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use
TW202112772A (zh) 作為腺苷受體拮抗劑之5-氮雜吲唑衍生物
WO2023125907A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EA046488B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[2,1-f][1,2,4]ТРИАЗИН-4-АМИНА В КАЧЕСТВЕ АГОНИСТОВ TLR7
WO2022143856A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
UA113436C2 (xx) 4-(ЗАМІЩЕНІ АМІНО)-7H-ПІРОЛО[2,3-d]ПІРИМІДИНИ ЯК ІНГІБІТОРИ LRRK2